miRNA clusters as therapeutic targets for hormone-resistant breast cancer.
miRNA clusters as therapeutic targets for hormone-resistant breast cancer.
复制标题
DOI：
10.1586/17446651.2015.1099430
复制
发表时间：
2015
影响因子：
3.2
通讯作者：
Croce CM
中科院分区：
文献类型：
--
作者：
Di Leva G;Cheung DG;Croce CM
MicroRNA是小的非编码RNA，其通常抑制信使RNA的翻译和稳定性，控制参与细胞过程如炎症、细胞周期调节、应激反应、分化、凋亡和迁移的基因。毫不奇怪，microRNA在癌症中也异常表达，并通过破坏这些重要的细胞功能促进肿瘤发生。在这篇综述中，我们首先广泛总结了microRNA在乳腺癌和雌激素受体α信号转导中的作用。然后，我们重点介绍目前已知的microRNA在抗激素治疗或耐内分泌药物中的作用。具体而言，我们将讨论涉及他莫昔芬（miR-221/222，181，101，519 a，301，375，342，451和let-7家族），氟维司群（miR-221/222，miR-200家族）和芳香酶抑制剂（miR-128和let-7家族）抗性的关键miRNA。
MicroRNAs are small non coding RNAs that typically inhibit the translation and stability of messenger RNAs, controlling genes involved in cellular processes such as inflammation, cell cycle regulation, stress response, differentiation, apoptosis, and migration. Not surprisingly, microRNAs are also aberrantly expressed in cancer and promote tumorigenesis by disrupting these vital cellular functions. In this review, we first broadly summarize the role of microRNAs in breast cancer and Estrogen Receptor alpha signaling. Then we focus on what is currently known about the role of microRNAs in anti-hormonal therapy or resistance to endocrine agents. Specifically, we will discuss key miRNAs involved in tamoxifen (miR-221/222, 181, 101, 519a, 301, 375, 342, 451, and the let-7 family), fulvestrant (miR-221/222, miR-200 family), and aromatase inhibitor (miR-128 and the let-7 family) resistance.